nach oben

American Journal of Cardiovascular Drugs

Erschienen in:

01.06.2016 | Systematic Review

Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?

verfasst von: Endalkachew A. Alamneh, Leanne Chalmers, Luke R. Bereznicki

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Background and Objectives

Atrial fibrillation (AF) and the associated risk of stroke are emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for stroke prevention has been widely reported from observational studies. In recent years, direct oral anticoagulants (DOACs) have been introduced for thromboprophylaxis. We conducted a systematic literature review to evaluate current practices of anticoagulation in AF, pharmacologic features and adoption patterns of DOACs, their impacts on proportion of eligible patients with AF who receive oral anticoagulants, persisting challenges and future prospects for optimal anticoagulation.

Literature Source and Selection Criteria

In conducting this review, we considered the results of relevant prospective and retrospective observational studies from real-world practice settings. PubMed (MEDLINE), Scopus (RIS), Google Scholar, EMBASE and Web of Science were used to source relevant literature. There were no date limitations, while language was limited to English. Selection was limited to articles from peer reviewed journals and related to our topic.

Results

Most studies identified in this review indicated suboptimal use of anticoagulants is a persisting challenge despite the availability of DOACs. Underuse of oral anticoagulants is apparent particularly in patients with a high risk of stroke. DOAC adoption trends are quite variable, with slow integration into clinical practice reported in most countries; there has been limited impact to date on prescribing practice.

Conclusion

Available data from clinical practice suggest that suboptimal oral anticoagulant use in patients with AF and poor compliance with guidelines still remain commonplace despite transition to a new era of anticoagulation featuring DOACs.

Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25.PubMedCrossRef

Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.PubMedCrossRef

Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746–51.PubMedPubMedCentralCrossRef

Freedman JE, Gersh BJ. Atrial fibrillation and stroke prevention in aging patients: what’s good can be even better. Circulation. 2014;130(2):129–31.PubMedCrossRef

Chugh SS, Roth GA, Gillum RF, Mensah GA. Global burden of atrial fibrillation in developed and developing nations. Glob Heart. 2014;9(1):113–9.PubMedCrossRef

Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014;11(11):639–54. doi:10.1038/nrcardio.2014.118.PubMedCrossRef

Ball J, Thompson DR, Ski CF, Carrington MJ, Gerber T, Stewart S. Estimating the current and future prevalence of atrial fibrillation in the Australian adult population. Med J Aust. 2015;202(1):32–5.PubMedCrossRef

Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol. 2013;167(6):2412–20.PubMedCrossRef

Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.PubMedCrossRef

10.

January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.PubMedCrossRef

11.

Foley J, Kirchhof P, Lip GY. Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all? Curr Vasc Pharmacol. 2014;12(3):373–83.PubMedCrossRef

12.

Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18–209.PubMedPubMedCentralCrossRef

13.

Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36(6):1115–9. doi:10.1161/01.STR.0000166053.83476.4a.PubMedCrossRef

14.

Reiffel JA. Atrial fibrillation and stroke: epidemiology. Am J Med. 2014;127(4):e15–6. doi:10.1016/j.amjmed.2013.06.002.

15.

Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8.PubMedCrossRef

16.

Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol. 2008;141(6):757–63. doi:10.1111/j.1365-2141.2008.07119.x.PubMedCrossRef

17.

Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.PubMedCrossRef

18.

Bassand JP. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace. 2012;14(3):312–24.PubMedPubMedCentralCrossRef

19.

Akao M, Chun YH, Wada H, et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol. 2013;61(4):260–6. doi:10.1016/j.jjcc.2012.12.002.PubMedCrossRef

20.

Bratland B, Hornnes MB. Warfarin therapy for atrial fibrillation in general practice–is bleeding risk underestimated? Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. 2014;134(2):175–9. doi:10.4045/tidsskr.13.0626.CrossRef

21.

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.PubMedCrossRef

22.

Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–106.PubMedCrossRef

23.

Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004;126(6):1938–45.PubMedCrossRef

24.

Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(2):84–91. doi:10.1161/circoutcomes.108.796185.PubMedCrossRef

25.

Cousins DH, Gerrett D, Warner B. A review of medication incidents reported to the National Reporting and Learning System in England and Wales over 6 years (2005–2010). Br J Clin Pharmacol. 2012;74(4):597–604. doi:10.1111/j.1365-2125.2011.04166.x.PubMedPubMedCentralCrossRef

26.

Nutescu EA, Shapiro NL, Chevalier A, Amin AN. A pharmacologic overview of current and emerging anticoagulants. Clevel Clin J Med. 2005;72(Suppl 1):S2–6.CrossRef

27.

Norgard NB, Dinicolantonio JJ, Topping TJ, Wee B. Novel anticoagulants in atrial fibrillation stroke prevention. Ther Adv Chronic Disease. 2012;3(3):123–36.CrossRef

28.

Armaganijan L, Eikelboom J, Healey JS, Morillo CA. New pharmacotherapy for stroke prevention in atrial fibrillation: update 2010. Adv Therapy. 2009;26(12):1058–71.CrossRef

29.

Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011;106(6):997–1011.PubMedCrossRef

30.

Odum LE, Cochran KA, Aistrope DS, Snella KA. The CHADS(2) versus the new CHA2DS2-VASc scoring systems for guiding antithrombotic treatment of patients with atrial fibrillation: review of the literature and recommendations for use. Pharmacotherapy. 2012;32(3):285–96.PubMedCrossRef

31.

Senoo K, Lane D, Lip GY. Stroke and bleeding risk in atrial fibrillation. Korean Circ J. 2014;44(5):281–90. doi:10.4070/kcj.2014.44.5.281.PubMedPubMedCentralCrossRef

32.

Dzeshka MS, Lane DA, Lip GY. Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2 DS2-VASc, R2 CHADS2, HAS-BLED, ATRIA, and more). Clin Cardiol. 2014;37(10):634–44.PubMedCrossRef

33.

Lip GY. Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary. J Thromb Haemost. 2013;11(4):615–26. doi:10.1111/jth.12140.PubMedCrossRef

34.

National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. Atrial Fibrillation: The Management of Atrial Fibrillation. London: National Institute for Health and Care Excellence (UK), Copyright (c) National Clinical Guidelince Center; 2014.

35.

Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.PubMedCrossRef

36.

Gamra H, Murin J, Chiang CE, Naditch-Brule L, Brette S, Steg PG. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis. 2014;107(2):77–87.PubMedCrossRef

37.

Mohammed MA, Marshall T, Nirantharakumar K, Stevens A, Fitzmaurice D. Patterns of warfarin use in subgroups of patients with atrial fibrillation: a cross-sectional analysis of 430 general practices in the United Kingdom. PLoS One. 2013;8(5):e61979.PubMedPubMedCentralCrossRef

38.

Bednarski J, Cieszewska E, Strzelecki A, Filipiak KJ. Anticoagulant and antiplatelet therapy for stroke prevention in atrial fibrillation patients in the clinical practice of a single district hospital in Poland. Kardiol Pol. 2013;71(12):1260–5.PubMedCrossRef

39.

Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13–9.e1. doi:10.1016/j.ahj.2011.09.011.

40.

Huisman MV, Lip GY, Diener HC, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J. 2014;167(3):329–34. doi:10.1016/j.ahj.2013.12.006.PubMedCrossRef

41.

Cullen MW, Kim S, Piccini JP, et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes. 2013;6(4):461–9.PubMedCrossRef

42.

Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events–European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6–14.PubMedPubMedCentralCrossRef

43.

Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30(10):1114–30. doi:10.1016/j.cjca.2014.08.001.PubMedCrossRef

44.

Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27(24):3018–26. doi:10.1093/eurheartj/ehl015.PubMedCrossRef

45.

Waldo AL, Becker RC, Tapson VF, Colgan KJ. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46(9):1729–36. doi:10.1016/j.jacc.2005.06.077.PubMedCrossRef

46.

McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001;161(20):2458–63.PubMedCrossRef

47.

Chan PS, Maddox TM, Tang F, Spinler S, Spertus JA. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol. 2011;108(8):1136–40.PubMedPubMedCentralCrossRef

48.

Akao M, Chun YH, Esato M, et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J. 2014;78(9):2166–72.PubMedCrossRef

49.

Wang C, Yang Z, Wang C, et al. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the china national stroke registry. J Stroke Cerebrovasc Dis. 2014;23(5):1157–63. doi:10.1016/j.jstrokecerebrovasdis.2013.10.006.PubMedCrossRef

50.

Ogilvie IM, Newton N, Welner SA. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45.e4.

51.

Piyaskulkaew C, Singh T, Szpunar S, Saravolatz L 2nd, Rosman H. CHA(2)DS(2)-VASc versus CHADS(2) for stroke risk assessment in low-risk patients with atrial fibrillation: a pilot study from a single center of the NCDR-PINNACLE registry. J Thromb Thrombolysis. 2014;37(4):400–3. doi:10.1007/s11239-013-0983-z.PubMedCrossRef

52.

Lip GY, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015;65(14):1385–94.PubMedCrossRef

53.

Barnes GD, Kaatz S, Winfield J, et al. Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)). J Thromb Thrombolysis. 2014;37(2):171–6.PubMedCrossRef

54.

Lip GY, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014;16(3):308–19. doi:10.1093/europace/eut373.PubMedCrossRef

55.

Suarez J, Piccini JP, Liang L, et al. International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. Am Heart J. 2012;163(5):804–11.PubMedPubMedCentralCrossRef

56.

Zimetbaum PJ, Thosani A, Yu HT, et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med. 2010;123(5):446–53.PubMedCrossRef

57.

Kimmel SE, Chen Z, Price M, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med. 2007;167(3):229–35.PubMedCrossRef

58.

Brandes A, Overgaard M, Plauborg L, et al. Guideline adherence of antithrombotic treatment initiated by general practitioners in patients with nonvalvular atrial fibrillation: a Danish survey. Clin Cardiol. 2013;36(7):427–32. doi:10.1002/clc.22133.PubMedCrossRef

59.

Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010:ehq278.

60.

Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3(6):624–31.PubMedPubMedCentralCrossRef

61.

De Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol. 2005;252(11):1316–21. doi:10.1007/s00415-005-0858-0.PubMedCrossRef

62.

Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244–52.PubMed

63.

Oldgren J, Healey JS, Ezekowitz M, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation. 2014;129(15):1568–76.PubMedCrossRef

64.

DeWilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart (British Cardiac Society). 2006;92(8):1064–70.CrossRef

65.

Reynolds MR, Shah J, Essebag V, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol. 2006;97(4):538–43. doi:10.1016/j.amjcard.2005.09.086.PubMedCrossRef

66.

Deitelzweig SB, Buysman E, Pinsky B, et al. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther. 2013;35(8):1201–10.PubMedCrossRef

67.

Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4(1):e001486. doi:10.1161/jaha.114.001486.PubMedPubMedCentralCrossRef

68.

Meiltz A, Zimmermann M, Urban P, Bloch A. Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace. 2008;10(6):674–80. doi:10.1093/europace/eun086.PubMedCrossRef

69.

Atarashi H, Inoue H, Okumura K, et al. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J. 2011;75(6):1328–33.PubMedCrossRef

70.

Lip G, Bassand J-P, Fitzmaurice D, et al. Inappropriate utilization of anticoagulation in patients with atrial fibrillation: the global anticoagulant registry in the field (garfield) registry. J Am Coll Cardiol. 2012;59(13s1):E670.CrossRef

71.

Holt TA, Hunter TD, Gunnarsson C, et al. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract. 2012;62(603):e710–7. doi:10.3399/bjgp12X656856.PubMedPubMedCentralCrossRef

72.

Barrios V, Calderon A, Escobar C, de la Figuera M. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol (Engl ed). 2012;65(1):47–53. doi:10.1016/j.recesp.2011.08.008.PubMedCrossRef

73.

Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart. 2013;99(16):1166–72. doi:10.1136/heartjnl-2012-303472.PubMedPubMedCentralCrossRef

74.

Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1–22. doi:10.2165/0003088-200948010-00001.PubMedCrossRef

75.

Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol. 2013;69(9):1617–33.PubMedCrossRef

76.

Haft JI. Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants. Clin Applied Thromb Hemost. 2013;19(3):241–8.

77.

Perez A, Eraso LH, Merli GJ. Implications of new anticoagulants in primary practice. Int J Clin Pract. 2013;67(2):139–56. doi:10.1111/ijcp.12023.PubMedCrossRef

78.

Connolly SJ, Wallentin L, Ezekowitz MD, et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation. 2013;128(3):237–43. doi:10.1161/circulationaha.112.001139.PubMedCrossRef

79.

Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625–51. doi:10.1093/europace/eut083.PubMedCrossRef

80.

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.PubMedCrossRef

81.

Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.PubMedCrossRef

82.

Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

83.

Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.PubMedCrossRef

84.

Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17. doi:10.1056/NEJMoa1007432.PubMedCrossRef

85.

Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635–41.PubMedCrossRef

86.

Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127(22):2166–76.PubMedCrossRef

87.

Sardar P, Chatterjee S, Lavie CJ, et al. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J Cardiol. 2015;179:279–87.PubMedCrossRef

88.

Verdecchia P, Angeli F, Bartolini C, et al. Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach. Expert Opin Drug Saf. 2015;14(1):7–20. doi:10.1517/14740338.2014.971009.PubMedCrossRef

89.

Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjoth F, Rosenzweig M, Lip GY. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med. 2014;127(7):650–6.e5.

90.

Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. doi:10.1016/s0140-6736(13)62343-0.PubMedCrossRef

91.

Labaf A, Carlwe M, Svensson PJ. Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden. Thromb J. 2014;12(1):29.PubMedPubMedCentralCrossRef

92.

Savelieva I, Camm AJ. Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin Cardiol. 2014;37(1):32–47.PubMedCrossRef

93.

Gonsalves WI, Pruthi RK, Patnaik MM, editors. The new oral anticoagulants in clinical practice. Mayo Clinic Proceedings: Elsevier; 2013.

94.

Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. Annu Rev Pharmacol Toxicol. 2012;52:79–99.PubMedCrossRef

95.

Lu Y, Branstad R, Karim RM, Asinger RW. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation. J Clin Pharm Ther. 2014;39(6):628–36.PubMedCrossRef

96.

Mohanty BD, Looser PM, Gokanapudy LR, et al. Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation. Vasc Med (London, England). 2014;19(3):190–204. doi:10.1177/1358863x14532869.

97.

Poulsen BK, Grove EL, Husted SE. New oral anticoagulants. Drugs. 2012;72(13):1739–53.PubMedCrossRef

98.

Salem JE, Sabouret P, Funck-Brentano C, Hulot JS. Pharmacology and mechanisms of action of new oral anticoagulants. Fundam Clin Pharmacol. 2015;29(1):10–20. doi:10.1111/fcp.12091.PubMedCrossRef

99.

Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. BMJ (Clinical research ed). 2014;348:g2116. doi:10.1136/bmj.g2116.PubMedCentral

100.

Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs. 2014;14(3):175–89. doi:10.1007/s40256-013-0061-0.PubMedCrossRef

101.

Arepally GM, Ortel TL. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? Annu Rev Med. 2015;66:241–53.PubMedCrossRef

102.

Bista D, Chalmers L, Bereznicki L, Peterson G. Potential use of NOACs in developing countries: pros and cons. Eur J Clin Pharmacol. 2014;70(7):817–28.PubMedCrossRef

103.

Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry, Phase II. Am J Med. 2015;128(12):1306–13.e1.

104.

Xu Y, Holbrook AM, Simpson CS, Dowlatshahi D, Johnson AP. Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. CMAJ open. 2013;1(3):E115–9.PubMedPubMedCentralCrossRef

105.

Steinberg BA, Holmes DN, Piccini JP, et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2013;2(6):e000535.PubMedPubMedCentralCrossRef

106.

Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation—quality and cost implications. Am J Med. 2014. doi:10.1016/j.amjmed.2014.05.013.

107.

Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584–9. doi:10.1160/th11-11-0784.PubMedCrossRef

108.

Sorea C, Georger F, Makhoul R. 0203: analysis of antithrombotic therapy in patients over 75 years with non-valvular atrial fibrillation: do we apply the guidelines to elderly subjects? Arch Cardiovasc Dis Suppl. 2014;6:4.

109.

Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):615–21. doi:10.1161/circoutcomes.112.967299.PubMedPubMedCentralCrossRef

110.

Biskupiak J, Ghate S, Hamilton M, et al. Oral anticoagulant (OAC) utilization in atrial fibrillation after the introduction of novel oral anticoagulants. J Am Coll Cardiol. 2014;63(12_S). doi:10.1016/S0735-1097(14)60326-0.

111.

Shah N, Gosch K, Chan P, Marzec L, Ting H. Use of novel oral anticoagulants for patients with non-valvular atrial fibrillation: results from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014;63(12_S). doi:10.1016/S0735-1097(14)60332-6.

112.

Gibbs H, Kakkar A. One year Australian outcome results of cohort 1 of the Global Anticoagulant Registry in the FIELD (GARFIELD) study. Heart, Lung Circ. 2013;22:S221-S.

113.

Hamilton M, Kawabata H, Liu X, Brixner D, Biskupiak J. Utilization patterns of anticoagulants in non-valvular atrial fibrillation after the entry of novel oral anticoagulants in the United States. Circulation. 2012;126(21 Supplement):A9664.

114.

Verdino RJ. Untreated atrial fibrillation in the United States of America: understanding the barriers and treatment options. J Saudi Heart Assoc. 2015;27(1):44–9.PubMedPubMedCentralCrossRef

115.

Deitelzweig S. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation. Cardiovasc Ther. 2014;32(2):74–81.PubMedCrossRef

116.

Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol. 2015;115(8):1095–101.PubMedPubMedCentralCrossRef

117.

Olesen JB, Sorensen R, Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013. Europace: 2015;17(2):187–93. doi:10.1093/europace/euu225.CrossRef

118.

Kakkar AK, Mueller I, Bassand JP, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013;8(5):e63479.PubMedPubMedCentralCrossRef

119.

Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open. 2013;3(5):e002758. doi:10.1136/bmjopen-2013-002758.PubMedPubMedCentralCrossRef

120.

Gorczyca-Michta I, Wozakowska-Kaplon B. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience. Kardiol Pol. 2015;73(2):85–93. doi:10.5603/KP.a2014.0168.PubMedCrossRef

121.

122.

Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation. 2012;125(1):159–64 (discussion 64).

123.

Hernandez Olmedo M, Suarez Fernandez C. Progress of anticoagulation therapy in atrial fibrillation. Med Clin. 2014. doi:10.1016/j.medcli.2014.07.018.

124.

Suryanarayan D, Schulman S. When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world—a problem or a myth ? Semin Thromb Hemost. 2014;40(8):852–9.PubMedCrossRef

125.

Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015;113(5):931–42.PubMedCrossRef

126.

Ebright J, Mousa SA. Oral Anticoagulants and status of antidotes for the reversal of bleeding risk. Clin Appl Thromb Hemost. 2015;21(2):105–14. doi:10.1177/1076029614545211.PubMedCrossRef

127.

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–9.PubMedCrossRef

128.

Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121(18):3554–62.PubMedCrossRef

129.

Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–20.PubMedCrossRef

130.

Burness CB. Idarucizumab: first global approval. Drugs. 2015;75(18):2155–61. doi:10.1007/s40265-015-0508-5.PubMedCrossRef

131.

Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–51.PubMedCrossRef

132.

Duran A, Sengupta N, Diamantopoulos A, et al. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer’s perspective. PharmacoEconomics. 2012;30(2):87–101.PubMedCrossRef

133.

Cutler DM, Everett W. Thinking outside the pillbox–medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17):1553–5.PubMedCrossRef

134.

Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154(1):1–11. doi:10.7326/0003-4819-154-1-201101040-00289.PubMedCrossRef

135.

Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123(22):2562–70. doi:10.1161/circulationaha.110.985655.PubMedCrossRef

136.

Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 2012;15(4):776–85.PubMedCrossRef

137.

Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–14.PubMedCrossRef

138.

Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants—defining the issues and the management strategies. Thromb Haemost. 2013;110(8):205–12. doi:10.1160/TH13-02-0150.PubMedCrossRef

139.

Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.PubMedCrossRef

140.

De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;109(4):569–79.PubMedCrossRef

Titel: Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
verfasst von: Endalkachew A. Alamneh
Leanne Chalmers
Luke R. Bereznicki
Publikationsdatum: 01.06.2016
Verlag: Springer International Publishing
Erschienen in: American Journal of Cardiovascular Drugs / Ausgabe 3/2016
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI: https://doi.org/10.1007/s40256-016-0161-8

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?

Abstract

Background and Objectives

Literature Source and Selection Criteria

Results

Conclusion

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background and Objectives

Literature Source and Selection Criteria

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Anti-Anginal and Metabolic Effects of Carvedilol and Atenolol in Patients with Stable Angina Pectoris: A Prospective, Randomized, Parallel, Open-Label Study

Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review

Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options

How May Proton Pump Inhibitors Impair Cardiovascular Health?

Efficacy of Short-Term Statin Treatment for the Prevention of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography/Percutaneous Coronary Intervention: A Meta-Analysis of 21 Randomized Controlled Trials

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie